单剂量口服格帕沙星与头孢克肟治疗男性单纯性淋病的比较。性传播疾病研究组。
Comparison of single-dose oral grepafloxacin with cefixime for treatment of uncomplicated gonorrhea in men. The STD Study Group.
作者信息
Hook E W, McCormack W M, Martin D, Jones R B, Bean K, Maroli A N
机构信息
University of Alabama at Birmingham and Jefferson County Health Department, 35294, USA.
出版信息
Antimicrob Agents Chemother. 1997 Aug;41(8):1843-5. doi: 10.1128/AAC.41.8.1843.
In a randomized open study, 351 male patients with uncomplicated gonorrhea were given single oral doses of grepafloxacin (400 mg) or cefixime (400 mg). In the 299 microbiologically evaluable patients, urethral infections were cured in 99% (147 of 149) of those receiving grepafloxacin and 97% (145 of 150) of those given cefixime. Eradication rates for both regimens were 100% in the 16% (47 of 299) of participants who were infected with penicillin-resistant Neisseria gonorrhoeae and 97% in the 21% (62 of 299) of participants infected with tetracycline-resistant strains. Grepafloxacin is a well-tolerated alternative to cefixime for treatment of uncomplicated gonorrhea in males.
在一项随机开放研究中，351例无并发症淋病男性患者分别单次口服格帕沙星（400毫克）或头孢克肟（400毫克）。在299例可进行微生物学评估的患者中，接受格帕沙星治疗的患者尿道感染治愈率为99%（149例中的147例），接受头孢克肟治疗的患者治愈率为97%（150例中的145例）。在感染耐青霉素淋病奈瑟菌的16%（299例中的47例）参与者中，两种治疗方案的根除率均为100%；在感染耐四环素菌株的21%（299例中的62例）参与者中，根除率为97%。对于男性无并发症淋病的治疗，格帕沙星是一种耐受性良好的替代头孢克肟的药物。
Zotero 插件